Skip to Content
Søg Menu

ASCO20: Osimertinib ændrer præmisserne for adjuverende behandling efter radikal operation af EGFR-positiv ikke-småcellet lungecancer

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Relateret indhold

Outstanding Results for the Treatment of Lung Cancer

/ Tony Mok
Lungecancer Play the Video 05:08
Jeanny B. Aragon-Ching

The Landscape of Treatment for Bladder Cancer Is Changing

/ Jeanny B. Aragon-Ching
Blærecancer Play the Video 05:32
Jeanny B. Aragon-Ching

Optimal Patient Population in the JAVELIN Bladder 100-trial

/ Jeanny B. Aragon-Ching
Blærecancer Play the Video 03:01
Thorgerdur Palsdottir

The Capio Model for Prostate Cancer Diagnostics

/ Thorgerdur Palsdottir
ASCO24Prostatacancer Play the Video 8:20
Joaquim Bellmunt

First-Line Maintenance Therapy with Avelumab Show Significantly Prolonged OS and PFS in Patients with Advanced Urothelial Cancer with Low Tumor Burden

/ Joaquim Bellmunt
ASCO24Blærecancer Play the Video 5:36
Cathy Burton

Paradigm Changes in Hodgkin’s Lymphoma Treatments

/ Cathy Burton
ASCO24Hodgkins lymfomLymfom Play the Video 19:00
Oluf Dimitri Røe

ASCO24: Very Exciting Steps for Early Diagnosis and Lung Cancer

/ Oluf Dimitri Røe
ASCO24Lungecancer Play the Video 6:15

Trastuzumab Deruxtecan Significantly Improves Progression-Free Survival in Breast Cancer Patients Previously Treated with Endocrine Therapy

/ Sofie Pohl
ASCO24
Oluf Dimitri Røe

Oluf Dimitri Røe: ASCO Is the Cradle of Oncology

/ Oluf Dimitri Røe
ASCO24 Play the Video 2:44
Back to top